Amgen (AMGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Shares of Amgen Inc. advanced 4.34% to $410.24 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index remaining mostly unchanged at 7,764.64 and ...

On September 8, 2026, CNBC reported that Novartis’ failed pelacarsen trial has raised the stakes for rival experimental ...

Amgen Inc. AMGN has reported encouraging topline outcomes from its Phase 3 OASIZ 301 study. The trial assessed the efficacy of dazodalibep in adult patients suffering from Sjögren’s disease ...

Amgen stock (ISIN US0311621009) stood at USD 406.04 on Nasdaq on September 24, 2026, leaving the shares 9.17 percent below ...

Amgen (AMGN) stock rose 4% after dazodalibep met Phase 3 trial goals for Sjögren's disease, with no FDA-approved competitors currently available.

Amgen (AMGN) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Amgen stock was last at USD 410.86 in New York trading on September 25, 2026, up USD 4.82 or 1.19 percent from the USD 406.04 ...

On 8, 2026, Bristol-Myers Squibb Company, E. R. Squibb & Sons, L.L.C., (collectively, “BMS”) and Ono Pharmaceutical Co., Ltd. (“Ono”) ...

The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) is joining the EMA in withdrawing Amgen Inc.’s Tavneos (avacopan) and has banned its use by any new patients as of Sept. 1. To allow ...

THOUSAND OAKS - Amgen (NASDAQ: AMGN) announced positive topline results from the Phase 3 OASIZ 301 study evaluating dazodalibep in adults with Sjogren's disease and moderate-to-severe systemic disease ...